CCR5 and CXCR4 Usage by Non-clade B Human Immunodeficiency Virus Type 1 Primary Isolates

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2002 Feb 28

PMID 11861874

Citations 14

Authors

Daniah A D Thompson

Emmanuel G Cormier

Tatjana Dragic

Affiliations

Soon will be listed here.

Abstract

CCR5 and CXCR4 usage has been studied extensively with a variety of clade B human immunodeficiency virus type 1 (HIV-1) isolates. The determinants of CCR5 coreceptor function are remarkably consistent, with a region critical for fusion and entry located in the CCR5 amino-terminal domain (Nt). In particular, negatively charged amino acids and sulfated tyrosines in the Nt are essential for gp120 binding to CCR5. The same types of residues are important for CXCR4-mediated viral fusion and entry, but they are dispersed throughout the extracellular domains of CXCR4, and their usage is isolate dependent. Here, we report on the determinants of CCR5 and CXCR4 coreceptor function for a panel of non-clade B isolates that are responsible for the majority of new HIV-1 infections worldwide. Consistent with clade B isolates, CXCR4 usage remains isolate dependent and is determined by the overall content of negatively charged and tyrosine residues. Residues in the Nt of CCR5 that are important for fusion and entry of clade B isolates are also important for the entry of all non-clade B HIV-1 isolates that we tested. Surprisingly, we found that in contrast to clade B isolates, a cluster of residues in the second extracellular loop of CCR5 significantly affects fusion and entry of all non-clade B isolates tested. This points to a different mechanism of CCR5 usage by these viruses and may have important implications for the development of HIV-1 inhibitors that target CCR5 coreceptor function.

Citing Articles

Potential Treatment of COVID-19 with Traditional Chinese Medicine: What Herbs Can Help Win the Battle with SARS-CoV-2?.

Li L, Wu Y, Wang J, Yan H, Lu J, Wang Y Engineering (Beijing). 2021; 19:139-152.

PMID: 34729244 PMC: 8552808. DOI: 10.1016/j.eng.2021.08.020.

[CCR5 antagonists and HIV-1 infection: Bases and consequences of this therapeutic approach].

Psomas K, Corbeau P, Reynes J Antibiotiques (Paris). 2020; 12(1):27-41.

PMID: 32288525 PMC: 7146793. DOI: 10.1016/j.antib.2010.01.006.

An extended CCR5 ECL2 peptide forms a helix that binds HIV-1 gp120 through non-specific hydrophobic interactions.

Abayev M, Moseri A, Tchaicheeyan O, Kessler N, Arshava B, Naider F FEBS J. 2015; 282(10):1906-1921.

PMID: 25703038 PMC: 4439283. DOI: 10.1111/febs.13243.

Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5).

Garcia-Perez J, Rueda P, Alcami J, Rognan D, Arenzana-Seisdedos F, Lagane B J Biol Chem. 2011; 286(38):33409-21.

PMID: 21775441 PMC: 3190905. DOI: 10.1074/jbc.M111.279596.

Direct observation of chemokine receptors 5 on T-lymphocyte cell surfaces using fluorescent metal nanoprobes 2: Approximation of CCR5 populations.

Zhang J, Fu Y, Li G, Zhao R, Lakowicz J Biochem Biophys Res Commun. 2011; 407(1):63-7.

PMID: 21356199 PMC: 3077572. DOI: 10.1016/j.bbrc.2011.02.104.

References

Farzan M, Choe H, Vaca L, Martin K, Sun Y, DESJARDINS E . A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J Virol. 1998; 72(2):1160-4. PMC: 124591. DOI: 10.1128/JVI.72.2.1160-1164.1998. View

Bennetts B, Teutsch S, Buhler M, Heard R, Stewart G . The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol. 1998; 58(1):52-9. DOI: 10.1016/s0198-8859(97)00207-3. View

BERGER E . HIV entry and tropism: the chemokine receptor connection. AIDS. 1997; 11 Suppl A:S3-16. View

Ross T, Bieniasz P, Cullen B . Multiple residues contribute to the inability of murine CCR-5 to function as a coreceptor for macrophage-tropic human immunodeficiency virus type 1 isolates. J Virol. 1998; 72(3):1918-24. PMC: 109483. DOI: 10.1128/JVI.72.3.1918-1924.1998. View

Tscherning C, Alaeus A, Fredriksson R, Bjorndal A, Deng H, Littman D . Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology. 1998; 241(2):181-8. DOI: 10.1006/viro.1997.8980. View

Rabut G, Konner J, Kajumo F, Moore J, Dragic T . Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1. J Virol. 1998; 72(4):3464-8. PMC: 109856. DOI: 10.1128/JVI.72.4.3464-3468.1998. View

Bazan H, Alkhatib G, Broder C, BERGER E . Patterns of CCR5, CXCR4, and CCR3 usage by envelope glycoproteins from human immunodeficiency virus type 1 primary isolates. J Virol. 1998; 72(5):4485-91. PMC: 109686. DOI: 10.1128/JVI.72.5.4485-4491.1998. View

Gao F, Robertson D, Carruthers C, Morrison S, Jian B, Chen Y . A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. J Virol. 1998; 72(7):5680-98. PMC: 110237. DOI: 10.1128/JVI.72.7.5680-5698.1998. View

Zhang L, He T, Huang Y, Chen Z, Guo Y, Wu S . Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1. J Virol. 1998; 72(11):9307-12. PMC: 110352. DOI: 10.1128/JVI.72.11.9307-9312.1998. View

10.

Genoud S, Kajumo F, Guo Y, Thompson D, Dragic T . CCR5-Mediated human immunodeficiency virus entry depends on an amino-terminal gp120-binding site and on the conformational integrity of all four extracellular domains. J Virol. 1999; 73(2):1645-8. PMC: 103992. DOI: 10.1128/JVI.73.2.1645-1648.1999. View

11.

Brelot A, Heveker N, Adema K, Hosie M, Willett B, Alizon M . Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses. J Virol. 1999; 73(4):2576-86. PMC: 104012. DOI: 10.1128/JVI.73.4.2576-2586.1999. View

12.

Zhang Y, Moore J . Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?. J Virol. 1999; 73(4):3443-8. PMC: 104110. DOI: 10.1128/JVI.73.4.3443-3448.1999. View

13.

Bjorndal A, Sonnerborg A, Tscherning C, Albert J, Fenyo E . Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res Hum Retroviruses. 1999; 15(7):647-53. DOI: 10.1089/088922299310944. View

14.

BERGER E, Murphy P, Farber J . Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999; 17:657-700. DOI: 10.1146/annurev.immunol.17.1.657. View

15.

Chabot D, Zhang P, Quinnan G, Broder C . Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates. J Virol. 1999; 73(8):6598-609. PMC: 112744. DOI: 10.1128/JVI.73.8.6598-6609.1999. View

16.

de Roda Husman A, van Rij R, Blaak H, Broersen S, Schuitemaker H . Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression. J Infect Dis. 1999; 180(4):1106-15. DOI: 10.1086/314987. View

17.

Hung C, Heyden N, Ratner L . Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. J Virol. 1999; 73(10):8216-26. PMC: 112839. DOI: 10.1128/JVI.73.10.8216-8226.1999. View

18.

Li S, Juarez J, Alali M, Dwyer D, Collman R, Cunningham A . Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates. J Virol. 1999; 73(12):9741-55. PMC: 113021. DOI: 10.1128/JVI.73.12.9741-9755.1999. View

19.

Blanpain C, Doranz B, Vakili J, Rucker J, Govaerts C, Baik S . Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein. J Biol Chem. 1999; 274(49):34719-27. DOI: 10.1074/jbc.274.49.34719. View

20.

Cormier E, Persuh M, Thompson D, Lin S, Sakmar T, Olson W . Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. Proc Natl Acad Sci U S A. 2000; 97(11):5762-7. PMC: 18507. DOI: 10.1073/pnas.97.11.5762. View